Product Description
Cerebral infarction refers to the necrosis of local brain tissue including nerve cells, glial cells and blood vessels due to the lack of blood supply. The root cause is the occlusion of extracranial or intracranial arteries supplying blood to the brain and the failure to obtain timely and adequate collateral circulation. The main purpose of treatment is to restore the nerve function of patients with cerebral infarction, which is caused by the phenomenon that the metabolic needs of local brain tissue and the possible blood supply exceed a certain limit. Cinepazide maleate can dilate blood vessels well, prevent vasospasm, and improve arterial blood supply. Cinepazidemaleate (Cinepazidemaleate) was developed by Sanofi-Aventis of France and was first listed in France in 1974, in Spain in 1980 and in China in 2002. Cinepazide maleate is a calcium channel blocker. By preventing Ca2+ from entering vascular smooth muscle cells across membranes, it relaxes vascular smooth muscle and dilates cerebral vessels, coronary vessels and peripheral vessels, thereby relieving vasospasm, reducing vascular resistance and increasing blood flow. In addition to this Chemicalbook, cinepazide maleate can also enhance the effects of adenosine and cyclic adenosine phosphate (cAMP) and reduce oxygen consumption; Inhibit cAMP phosphodiesterase, increase the amount of cAMP; Improve the flexibility and deformability of red blood cells and the ability to pass through capillaries, reduce blood viscosity and improve microcirculation; Improve cerebral blood flow, improve cell nutrition, energy metabolism and anti-ischemia and hypoxia ability, protect brain cell function; Inhibit platelet aggregation, reduce the production of oxygen free radicals, reduce neutrophils' chemotaxis to vascular endothelial cells, improve the toughness and deformability of red blood cells, and reduce blood viscosity, thereby improving microcirculation perfusion. Cinepazide maleate is mainly used in the treatment of cardiovascular and cerebrovascular diseases, especially for cerebral arteriosclerosis, transient ischemic attack, cerebral thrombosis, cerebral embolism, sequelae of cerebral hemorrhage and sequelae of cerebral trauma. Moreover, it has certain curative effect on cardiovascular disease and peripheral vascular disease. According to the analysis report of the Information Department of the China Chemical and Pharmaceutical Industry Association, cinepazide maleate in sample hospitals reached 385 million yuan in 2009, an increase of 17.04% over the previous year.
Pharmacological action
Adenosine synergistic effect: Cinepazide maleate has a unique adenosine synergistic effect by blocking cell reabsorption of adenosine and inhibiting adenosine deaminase activity, blocking adenosine inactivation process, delaying adenosine metabolism process, thereby increasing the concentration of endogenous adenosine in the affected area and enhancing the biological role of endogenous adenosine. Vasodilator effect: Cinepazide maleate has weak calcium ion blocking effect, Chemicalbook can antagonize calcium ion overload, significantly dilate blood vessels, and has good spasmolysis and dilation effect on coronary arteries, cerebrovascular and peripheral blood vessels. Improved hemorheology: Cinepezide maleate can inhibit platelet aggregation, reduce the production of oxygen free radicals, reduce neutrophil chemotaxis to vascular endothelial cells, increase cell toughness and deformability, and reduce blood viscosity, thereby improving microcirculation perfusion.
Audited Supplier 
){kind=link}
){kind=link}